14 results about "Liver enzyme" patented technology

How to treat injuries or conditions associated with CNS edema [Solution] This technology relates to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the method includes reducing late neurological exacerbations or preventing death, reducing midline deviation of the brain, reducing the degree of functional impairment in subjects, neutralizing blood glucose levels in subjects receiving SUR1-TRPM4 channel inhibitors, preventing cerebral swelling, treating injuries or conditions associated with CNS edema while monitoring liver enzyme activity, or treating injuries or conditions associated with CNS edema while monitoring cardiac activity.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

This invention relates to the field of livestock and poultry breeding and food safety testing technology, and in particular to a method for assessing copper exposure hepatotoxicity based on the endoplasmic reticulum stress-endoplasmic reticulum autophagy axis and its application. This method obtains liver tissue samples or in vitro cultured hepatocyte samples from copper-exposed subjects, and jointly detects the expression levels of key markers of the endoplasmic reticulum stress pathway and characteristic markers of the endoplasmic reticulum autophagy pathway. Combined with two-way pharmacological validation, a grading assessment standard for copper exposure hepatotoxicity is established. This invention overcomes the shortcomings of traditional liver enzyme indicators, such as low sensitivity and strong lag, and has the advantages of early warning, high specificity, and reliable results. It can be widely applied to scenarios such as determining the copper safety threshold in livestock and poultry feed, early screening for copper exposure hepatotoxicity, assessment of copper pollution ecological risks, and screening of copper toxicity protectants, providing technical support for ensuring animal health and the safety of animal-derived food.

This article describes methods, compositions, and systems derived from uncultured microorganisms that can be used to supplement liver enzyme deficiencies.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

The invention discloses a drug-resistant main protease inhibitor with stable metabolism and application thereof in preparation of antiviral drugs. In the main protease inhibitor, a group C not only can be effectively combined with an active pocket of main protease, but also the combination mainly depends on the 163rd amino acid site of the main protease; meanwhile, the group C is relatively difficult to oxidize, so that the main protease inhibitor can show basically consistent inhibitory activity to both mutant strains and wild strains, viruses do not generate drug resistance to the main protease inhibitor, and the main protease inhibitor can tolerate liver drug enzyme metabolism, has excellent drug-resistant activity and metabolic stability, and can be used for preparing the main protease inhibitor. In use, a liver drug enzyme inhibitor does not need to be used cooperatively, and reduction of self liver function decline and toxic and side effects caused by medicine taking is facilitated. In addition, the group A not only can further improve the inhibitory activity of the main protease inhibitor on the main protease, but also can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the ring B mainly plays a role in further improving the inhibitory activity of the main protease inhibitor on the main protease.

The application belongs to the technical field of microorganisms and their application, and specifically discloses a mucinophilic Akkermansia strain, a high-activity reserved inactivation method of the strain and application of the strain. The strain has a preservation number of CGMCC No. 33955, and when the strain is cultured in a mucin only carbon source culture medium for 48 hours, the OD600 value reaches 1.32 and the acetic acid yield is 18.3 mmol / L. The inactivation method uses a solution containing sulfated dextran, sucrose and epsilon-polylysine as a composite protective agent, and after the solution is mixed with the bacterial solution, the mixture is incubated at 45 DEG C to 50 DEG C for 16 min to 20 min. The inactivated strain reduces inflammation and protects lung vascular function through the "gut-lung axis", and in a MCT-induced PAH rat model, the intervention effect is close to sildenafil, and there is no increase in liver enzymes, the serum TNF-alpha and IL-6 are reduced, and the problems of large side effects and low activity reservation of existing PAH intervention are solved.

A method for identifying a cause of elevated liver enzymes includes receiving new patient data, receiving a machine-learning based diagnostic model and a knowledge based diagnostic model, determining whether the machine-learning based diagnostic model indicates a cause of elevated liver enzymes for the new patient data, and in a case where the machine-learning based diagnostic model indicates the cause of elevated liver enzymes for the new patient data, assessing the cause of elevated liver enzymes using the knowledge based diagnostic model.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

The invention discloses a drug-resistant main protease inhibitor with stable metabolism and application thereof in preparation of antiviral drugs. In the main protease inhibitor, a group C not only can be effectively combined with an active pocket of main protease, but also the combination mainly depends on the 163rd amino acid site of the main protease; meanwhile, the group C is relatively difficult to oxidize, so that the main protease inhibitor can show basically consistent inhibitory activity to both mutant strains and wild strains, viruses do not generate drug resistance to the main protease inhibitor, and the main protease inhibitor can tolerate liver drug enzyme metabolism, has excellent drug-resistant activity and metabolic stability, and can be used for preparing the main protease inhibitor. In use, a liver drug enzyme inhibitor does not need to be used cooperatively, and reduction of self liver function decline and toxic and side effects caused by medicine taking is facilitated. In addition, the group A not only can further improve the inhibitory activity of the main protease inhibitor on the main protease, but also can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the ring B mainly plays a role in further improving the inhibitory activity of the main protease inhibitor on the main protease.

The invention discloses a broccoli extract, a preparation method thereof and application of the broccoli extract in preparation of products for adjuvant therapy of fatty liver diseases related to metabolic dysfunction, belongs to the technical field of plant extracts, and particularly relates to a preparation method of the broccoli extract, which comprises the following steps: cleaning, cutting and drying broccoli leaves to obtain dried broccoli leaves, crushing, sieving, and drying to obtain the broccoli extract. And dispersing the broccoli leaf powder in distilled water, carrying out ultrasonic extraction to obtain a broccoli leaf extracting solution, centrifuging, collecting supernate, and carrying out vacuum freeze drying to obtain the broccoli extract. The broccoli extract is applied to preparation of products for prevention and / or adjuvant therapy of fatty liver diseases related to metabolic dysfunction. The broccoli leaf extract prepared by the preparation method provided by the invention is proved to be capable of remarkably inhibiting weight gain, improving glucose tolerance and insulin sensitivity and reducing serum lipid level and liver enzyme activity by utilizing a mouse high fat diet induced MAFLD prevention and treatment model.

The application belongs to the technical field of biological medicine, and particularly relates to POFUT1 The application discloses an application of a gene function inhibitor in preparation of a drug for treating cholestatic liver disease. POFUT1 It is found for the first time that inhibition of the function of the gene can significantly reduce the degree of liver lesion of cholestatic liver disease. POFUT1 The deletion of the gene can significantly reduce serum liver enzyme, bile acid and bilirubin levels, reduce liver inflammatory cell infiltration and collagen deposition. Further verification by AAV8-mediated RNA interference technology shows that targeted silencing of the gene in liver cells can effectively alleviate liver injury and liver fibrosis. POFUT1 The application provides a novel treatment target and strategy for cholestatic liver disease, and has a wide clinical application prospect.